Since their introduction in 2010, non-vitamin K oral anticoagulants (NOACs) changed the landscape of stroke prevention in patients with atrial fibrillation (AF). Because of their favorable benefit-harm profile, the fixed dose administration, the no need for laboratory monitoring and dose adjustment, NOAC prescription increased rapidly and overcome the use of vitamin K antagonists (VKAs) [1,2].
